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Abstract 
Background: SARS-CoV-2 poses a considerable threat to those living in residential aged care facilities (RACF). RACF 
COVID-19 outbreaks have been characterised by the rapid spread of infection and high rates of severe disease and 
associated mortality. Despite a growing body of evidence supporting airborne transmission of SARS-CoV-2, current 
infection control measures in RACF including hand hygiene, social distancing, and sterilisation of surfaces, focus on 
contact and droplet transmission. Germicidal ultraviolet (GUV) light has been used widely to prevent airborne patho-
gen transmission. Our aim is to investigate the efficacy of GUV technology in reducing the risk of SARS-CoV-2 infec-
tion in RACF.
Methods: A multicentre, two-arm double-crossover, randomised controlled trial will be conducted to determine 
the efficacy of GUV devices to reduce respiratory viral transmission in RACF, as an adjunct to existing infection control 
measures. The study will be conducted in partnership with three aged care providers in metropolitan and regional 
South Australia. RACF will be separated into paired within-site zones, then randomised to intervention order (GUV 
or control). The initial 6-week period will be followed by a 2-week washout before crossover to the second 6-week 
period. After accounting for estimated within-zone and within-facility correlations of infection, and baseline infection 
rates (10 per 100 person-days), a sample size of n = 8 zones (n = 40 residents/zone) will provide 89% power to detect 
a 50% reduction in symptomatic infection rate. The primary outcome will be the incidence rate ratio of combined 
symptomatic respiratory infections for intervention versus control. Secondary outcomes include incidence rates of 
hospitalisation for complications associated with respiratory infection; respiratory virus detection in facility air and 
fomite samples; rates of laboratory confirmed respiratory illnesses and genomic characteristics.
Discussion: Measures that can be deployed rapidly into RACF, that avoid the requirement for changes in resident 
and staff behaviour, and that are effective in reducing the risk of airborne SARS-CoV-2 transmission, would provide 
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Background
Outbreaks of SARS-CoV-2 infections (COVID-19) in 
residential aged care facilities (e.g. nursing homes) have 
proven catastrophic [1]. Rapid transmission of SARS-
CoV-2 between residents, combined with the increased 
likelihood of severe illness or death due to resident age, 
comorbidities, and frailty, have resulted in the highest 
overall mortality rate of any population [1].
The principal infection control measures employed in 
most settings, including RACF, currently focus on the 
transmission of SARS-CoV-2 in the form of respiratory 
droplets. Transmission occurs via close contact with an 
infectious person or via contact with a contaminated 
surface. Prevention measures include social distancing, 
the use of masks, hand hygiene, and surface sterilisation. 
However, there have been many instances of transmission 
occurring despite strict adherence to such infection con-
trol strategies [2, 3]. As a result, there is growing concern 
that airborne transmission in the form of bioaerosols, 
which can remain suspended in the air for a considerable 
period, can contribute to transmission [4–6].
During the COVID-19 pandemic, our understanding 
of modes of SARS-CoV-2 transmission has evolved [7]. 
An increasing body of evidence supports bioaerosol-
mediated spread [4–6, 8]. While the overall contribution 
of this transmission route remains uncertain, an air-
borne component of COVID-19 transmission would be 
consistent with other respiratory viruses, such as SARS-
CoV-1, Middle Eastern respiratory syndrome coronavirus 
(MERS-CoV), and influenza [9, 10].
Measures to prevent airborne transmission of viral 
and bacterial pathogens in other clinical and non-clinical 
contexts, including reduced air-recirculation, air-filtra-
tion, and the use of germicidal ultraviolet (GUV) light 
[11], have considerable potential to reduce COVID-19 
transmission in residential aged care. Such approaches 
can be applied in parallel to existing infection prevention 
measures, and implemented in a rapid, cost-effective, and 
non-disruptive manner. Importantly, they are not reli-
ant on changes in the behaviour or practices of residents 
or staff as, for example, required for safe use of Personal 
Protective Equipment (PPE).
High levels of air exchange can be prohibitively expen-
sive due to heating and cooling costs [11]. Filtration 
systems require ongoing maintenance to ensure efficacy 
and modification of existing air conditioning systems. As 
such, GUV has a number of important advantages over 
other options in the context of residential aged care facil-
ities (RACF). GUV is highly effective in killing viral path-
ogens, including a 98.2% reduction in airborne influenza 
[12], and a 400-fold decrease in SARS-CoV-1 infectious 
virus [13], and is effective in other human coronaviruses, 
such as alpha HCoV-229E and beta HCoV-OC43 [14].
GUV technology is commercially available in several 
different modalities. Upper-room GUV systems direct 
ultraviolet rays into the upper air zone and exposing 
air as it circulates through natural convection. Upper-
room GUV (with effective air-mixing) has been shown 
to reduce airborne tuberculosis transmission at a rate 
equivalent to implementing a high volume of mechani-
cal air ventilation (replacing the air volume of the room 
24 times per hour) [15]. Similarly, when GUV has been 
deployed as “in-duct” or standalone fan-based systems, it 
has been shown to result in significant reductions in both 
viral viability and rates of symptomatic respiratory infec-
tions [16]. These GUV modalities therefore allow deploy-
ment to be tailored to the particular characteristics and 
layout of individual RACF including proximity to resi-
dents and staff to ensure safety.
We describe a multicentre, two-arm double crossover, 
randomised controlled trial of a facility-level intervention 
involving the use of GUV light devices to reduce rates of 
airborne respiratory viral transmission in residential aged 
care settings.
Methods/design
The Prevention of SARS-CoV-2 (COVID-19) transmission 
in residential aged care using ultraviolet light (PETRA) 
study is registered in the Australian and New Zealand 
Clinical Trials Registry ACTRN12621000567820. A pub-
lication reporting the main study outcomes will be pub-
lished in accordance with the Consolidated Standards of 
Reporting Trials (CONSORT) statement [17].
Study design and setting
The PETRA study is a multicentre, two-arm double 
crossover, randomised, non-blinded controlled trial, with 
the two arms allocated to intervention order in a 1:1 ratio 
considerable benefit in safeguarding a highly vulnerable population. In addition, such measures might substantially 
reduce rates of other respiratory viruses, which contribute considerably to resident morbidity and mortality.
Trial registration Australian and New Zealand Clinical Trials Registry ACTRN12621000567820 (registered on 14th May, 
2021).
Keywords: SARS-CoV-2, COVID-19, Germicidal ultraviolet light, Residential aged care, Health care quality, Respiratory 
virus infection, Transmission
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(Fig.  1). Building characteristics of RACF vary, includ-
ing by age, layout, occupancy, rates of air change, and air 
ventilation systems. This variation requires the deploy-
ment of GUV devices in a manner that is facility-specific, 
but which also provides a consistent level of air treatment 
across facilities. The deployment of GUV devices focuses 
on communal use areas, including corridors, lobbies, din-
ing rooms, and occasional recreation areas. No devices 
will be placed within resident rooms, amenities, or staff-
only areas. Devices will be systematically deployed across 
the communal use areas of each facility to ensure consist-
ent volumes of air are irradiated across facilities.
RACF within metropolitan and regional [18] South 
Australia will be considered for recruitment if they pos-
sess the ability to sub-divide communal living areas into 
discrete areas that enable a concurrent comparison of 
interventions, with the facility cohorts otherwise subject 
to the same facility practices (e.g. environmental clean-
ing, staffing, and social distancing). Each area will be ran-
domly allocated to receive GUV light air treatment, or no 
air treatment, for the 6-week duration of the first period, 
followed by a 2-week washout period and then crossover 
of treatments for the second 6-week period. Cases of res-
piratory viral infections will be continuously monitored 
throughout the study, with air and environmental sam-
ples collected weekly for the duration of the study.
Intervention
The intervention will involve the commercially available 
Laftech GUV appliances: UV-FLOW-C wall- and ceiling-
mounted system, UV-FAN-XS wall-mounted air puri-
fier, and UV-FAN M2/95HP air purification device (LAF 
Technologies, Melbourne, Australia). We will implement 
the combined use of two GUV approaches: wall- and 
ceiling-mounted GUV devices situated in locations that 
provide air sterilisation of shared spaces, such as dining 
areas, and connecting corridors and spaces between resi-
dent rooms, with additional units providing coverage to 
high traffic spaces, such as lift areas; and portable stan-
dalone fan-driven units used in occasional areas, such 
as activity halls and chapels (employed during and fol-
lowing area use). GUV devices will be installed in study 
zones within each facility. Zones will be paired within 
facilities, with one zone in each pair randomised to the 
intervention or control condition for the first period. 
Similar deployment of GUV devices in paired areas will 
be employed across each zone.
GUV units will be switched off during control periods 
and run continuously during intervention periods. Six-
week intervention periods will be divided by a 2-week 
“washout” period to account for viral incubation periods, 
where all devices will be off, before crossover to the recip-
rocal intervention (Fig. 1). An open trial approach will be 
employed, without masking or blinding. Any changes in 
existing infection control practices will be recorded. The 
intervention will be implemented for two consecutive 




The primary outcome will be the incidence rate ratio of 
combined symptomatic respiratory infections for the 
intervention group versus the control group. The study 
will utilise the existing framework for surveillance of 
influenza-like illness (ILI) in RACF. The guidelines pub-
lished by both national (Communicable Disease Network 
Australia) [19] and local authorities (Communicable Dis-
eases Control Branch of South Australia) [20] define ILI 
in RACF based on European guidelines [21]. The existing 
guidelines stipulate that residents meeting the ILI defini-
tion, including symptoms of fever, cough, or sore throat, 
should be discussed with the treating general practitioner 
and undergo testing for influenza by nucleic acid amplifi-
cation using a nose and/or throat swab [19, 20]. To ensure 
thorough and consistent case identification, according 
Fig. 1 PETRA Trial Stages. Designated zones within RACF will be paired, with one zone in each pair randomised to the active or control condition 
for the first intervention period. Similar deployment of GUV devices in paired areas will be employed across each zone. GUV units will be switched 
off during control periods and run continuously during active periods. Six-week treatment periods will be divided by a 2-week “washout” period to 
account for viral incubation periods, before crossover to the reciprocal intervention
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to study definitions, the study manager/coordinator or 
study research nurse will liaise directly with facility staff 
for the duration of the study to capture this information.
During the intervention periods (Fig. 1; Table 1), iden-
tification of cases of symptomatic respiratory viral infec-
tion will be based on the existing clinical definition of ILI. 
RACF clinical team representatives will follow the facil-
ity’s standard surveillance program, and will complete a 
symptomatic respiratory infection data capture sheet, 
which will serve as the data collection instrument for the 
PETRA trial. Multiple episodes of infection in the same 
resident will be counted as case occasions for the same 
resident provided that the following criteria are met:
1. At least 2 weeks have passed since the initial case def-
inition was met.
2. The symptoms triggering the subsequent case defini-
tion have developed acutely (within 72  h of record-
ing).
However,
3. If the same pathogen is detected for both episodes, 
these will be considered one episode of infection, not 
two.
In accordance with current guidelines, residents meet-
ing the ILI definition should undergo subsequent pathol-
ogy testing. Participating facilities will request medical 
officers send respiratory swab to a pathology service for 
diagnostic testing of viral respiratory pathogens includ-
ing: SARS-CoV-2, influenza A, influenza B, parainfluenza 
virus 1, 2, 3, and 4, adenovirus, rhinovirus, human metap-
neumovirus, and respiratory syncytial virus. Patients will 
have met the primary outcome based on fulfilling the 
symptomatic respiratory infection clinical definition, 
even if no swab was performed or if the swab result is 
negative. However, data on swab results will be obtained 
from pathology services. Those who meet the clinical def-
inition and also have a positive diagnostic result will have 
met the definition of a confirmed symptomatic respira-
tory viral infection. The numbers of confirmed respira-
tory infection cases for each respiratory pathogen tested 
will be determined and analysed as a secondary outcome.
Secondary outcomes
Outcome 1 Incidence rates of hospitalisation (number of 
hospitalisations per 100 person-days followed) for com-
plications associated with respiratory infections. Hospi-
tal admissions, or presentations at hospital emergency 
departments for complications associated with acute 
respiratory infections, will be recorded through facility 
notes, including viral diagnostics and time.
Outcome 2 Respiratory virus detection in facility air 
samples. In addition to assessing symptomatic respira-
tory viral infections, presence of viral RNA/DNA within 
RACF will be measured. The methodology used is not 
designed to distinguish between viable and non-viable 
viral particles, and these environmental assessments are 
not intended as a measure of infection risk. Rather, they 
provide a snapshot of the level of detectable viruses in 
the environment that could be missed from only testing 
symptomatic residents (i.e. as generated by asymptomatic 
staff, visitors or residents). Viral shedding by asympto-
matic individuals has indeed been described in relation 
to both common respiratory viruses [22] and COVID-
19 [23]. As an indirect measure of viral particle load, 
Table 1 PETRA study protocol timeline
GUV germicidal ultraviolet light; RACF residential aged care facilities; UV-C ultraviolet C
Pre-treatment Weeks 1–6 Weeks 7–8 Weeks 9–14 Post-treatment
RACF eligibility assessment ●
RACF recruitment ●




Design GUV device layout per zone ●
Install GUV devices ●
Quality control of UV-C light ● ●
Zone randomisation ●
Routine monitoring of respiratory viral infections ● ●
Weekly air sampling of viral particles ● ●
Weekly fomite sampling of viral particles ● ●
Viral sequencing ●
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this study component will provide an additional basis to 
assess intervention impact.
Assessment of airborne respiratory virus presence will 
be performed based on air sample collection at the end 
of each study week (Coriolis micro liquid output air sam-
pler; Bertin Instruments, Fortitude Valley, Queensland) 
[24, 25]. A sample collection protocol sufficient for the 
detection of aerosol-borne Respiratory Syncytial Virus 
(RSV) and influenza [24, 25] as well as for levels of cir-
culating COVID-19 particles reported in healthcare envi-
ronments [26] will be employed. Viral particles in the air 
will be determined using realtime, multiplexed versions 
of polymerase chain reaction assays used in the routine 
diagnostic respiratory assay.
Outcome 3 Respiratory viral detection in facility fomite 
samples. Samples will be collected from non-absorbent 
fomites with pre-wetted (0.25 strength Ringer’s solution) 
polyester-tipped swabs, using a fixed area template [27]. 
Presence of viral RNA/DNA in fomite samples will be 
determined using an identical method to that used for air 
samples. The selection of surfaces will include common 
touch-points and surfaces encountered in shared areas 
(e.g. lift buttons, door handles), with sample collection 
performed at the end of each study week for the duration 
of the study schedule (Table 1).
Outcome 4 Incidence rates of laboratory-confirmed 
respiratory illnesses and genomic characteristics. Data 
will be captured on specimens sent to pathology services 
for respiratory virus testing during the study period. Inci-
dence rates will be calculated for individual respiratory 
viruses previously described. Viral sequencing will be 
performed on the nucleic acid extract of laboratory-con-
firmed positive specimens to determine epidemiological 
links.
In addition to the specified study outcomes, a number 
of other variables will be recorded. These will include air 
ventilation rates, carbon dioxide levels, and facility lock-
downs in response to outbreaks of notifiable infections or 
infections associated in rapid spread or high infectivity. 
For example, the identification of three or more cases of 
influenza-like illness occurring within 72 h in residents, 
or a sudden increase in influenza-like cases, or one case 
of influenza confirmed by any laboratory testing method 
in the presence of other reported influenza-like illness 
cases, constitutes an outbreak and triggers specific con-
tainment measures [19]. The detection of SARS-CoV-2 
is referred to as a COVID-19 outbreak. Any infection-
related changes in facility operation, such as facility-level 
vaccination rates, will also be recorded.
Facility participation
RACF participation is at the discretion of the provider’s 
senior management and in consideration of the best 
interest of residents. Facilities will have the option to 
withdraw from the trial at any stage. Informed consent 
will not be sought from individual aged care residents. 
However, individual residents and their families will be 
communicated with prior to and throughout the trial by 
the study team.
Governance
The study will comply with the National Health and Med-
ical Research Council (NHMRC) Australian Code for the 
Responsible Conduct of Research. A Clinical Trials Mem-
orandum of Understanding will be established between 
all RACF and the South Australian Health and Medical 
Research Institute (SAHMRI). A Study Protocol Steering 
Committee will be established to monitor trial progress 
and its ongoing ability to meet the objectives. Risk and 
financial management will comply with SAHMRI’s insti-
tutional policies. Consumer involvement will continue to 
be gathered through existing consumer reference groups 
at SAHMRI.
Sample size calculation
Based on a cluster randomised two-arm double-crosso-
ver design, in which each RACF zone is assigned to both 
the intervention and the control condition twice (once 
for each condition in each of two consecutive respiratory 
infection seasons), a sample size of n = 8 RACF zones 
(across five facilities) with an average size of n = 40 occu-
pied beds per zone, will provide 89% power to detect a 
50% reduction in rate of symptomatic infections, i.e. five 
per 100 person-days in the intervention group versus 10 
per 100 person-days in the control group. This calcula-
tion assumes an average of 35 days of follow-up for each 
subject for each of the four 6-week intervention periods 
providing 40 × 35 = 1400 person-days of follow-up per 
zone, a coefficient of variation for the zone event rate 
within each treatment of 50%, a 20% loss-to follow-up, 
and an intra-class correlation (ICC) for zones of ρ = 0.20 
resulting in a variance inflation factor (VIF) of VIF = (1 
− ρ)/4 = 0.2 i.e. 20% of the total number of zones and 
subjects required for a parallel group trial [28]. In sum-
mary, 8 zones with an average of 40 subjects per zone and 
35 days follow-up per subject across each of the four sep-
arate treatment periods will be required for this double 
crossover trial.
Statistical considerations
Primary analysis on the difference in infection incidence 
rates between the two periods will be assessed using 
mixed effects Poisson regression with fixed effects for 
the intervention group, intervention order, intervention 
period, and a period-to-intervention interaction term 
in order to assess for a possible intervention-to-period 
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interaction effect. The logarithm of the duration of expo-
sure to each intervention (person-days) will be included 
in the model as an offset term. The zone and facility will 
be included as random intercepts with zones nested 
within facilities. As a sensitivity analysis, we will also 
assess differences in infection incidence rates using wider 
time-windows for each testing period in order to account 
for the median incubation period of respiratory infection 
by up to four days, depending on the specific virus [29]. 
Analysis will be performed using Stata version 17. A two-
sided type-one error rate of alpha = 0.05 will be used to 
indicate statistical significance.
Discussion
The PETRA study aims to evaluate the feasibility and 
effectiveness of retrofitting GUV devices into RACF to 
combat respiratory virus outbreaks, including COVID-
19. Despite clear potential for airborne transmission to 
contribute to COVID-19 outbreaks in RACF [30], cur-
rent strategies employed to protect the wider community, 
including for more than 210,000 Australians currently 
living in residential aged care, do not include any meas-
ures to address this specific threat. Reductions to the 
risk of COVID-19 viral transmission within this vulner-
able population could prevent considerable loss of life. 
In addition to the threat of COVID-19, this study will 
address the burden of other respiratory pathogens, such 
as RSV and influenza, that are common causes of consid-
erable morbidity in aged care settings and transmissible 
via bioaerosols [6, 31, 32].
Commercially available upper-room GUV is an exist-
ing and validated technology. Previously identified 
as a potential solution for multi- and extensive drug-
resistant pathogens [33], GUV has proven highly effica-
cious against airborne viruses, including influenza and 
SARS-CoV-1 [12, 13]. Upper-room GUV systems direct 
GUV light into the upper air zone and treat air as it cir-
culates through natural convection. GUV light can also 
be enclosed within units that draw air into a germicidal 
compartment.
By assessing a potentially applicable environmental 
infection control strategy, we believe our study addresses 
a critically important public health need. Moreover, 
results from this study could potentially advocate for 
the rapid and cheap translation to additional RACF and 
other high-risk settings to reduce the risk of respiratory 
illness and mortality in our most vulnerable populations.
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